Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease - Schmid, Ulrike; Weber, Benjamin; Sarr, Celine; Freiwald, Matthias (BMC pulmonary medicine, 2021)
Keywords: Clinical trials; Critical Care Medicine; Diarrhea; Dose-response relationship (Biochemistry); Drug dosages; Drug therapy; Enzymes; Exposure–safety relationship; Fibrosis; Idiopathic pulmonary fibrosis; Intensive; Internal Medicine; Labeling; Laboratories; Liver; Liver enzyme elevation; Lung diseases; Lung diseases, Interstitial; Medicine; Medicine & Public Health; Nintedanib; Patients; Pharmacokinetics; Pharmacology, Experimental; Phenotypes; Plasma; Pneumology/Respiratory System; Progressive fibrosing ILDs; Pulmonary fibrosis; Pulmonology; Scleroderma; Scleroderma (Disease); Sex differences; Systemic scleroderma; Systemic sclerosis; Systemic sclerosis-associated interstitial lung disease; Transaminase; Germany; United States--US; Nintedanib; Exposure–safety relationship; Progressive fibrosing ILDs; Idiopathic pulmonary fibrosis; Liver enzyme elevation; Systemic sclerosis-associated interstitial lung disease